Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ODYY ODYSSEY GROUP INTL INC
0.135-0.005-3.57%
Close
02/04 09:30 ET
High
0.144
Open
0.140
Turnover
41.38K
Low
0.135
Pre Close
0.140
Volume
300.29K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Odyssey Health Completes Phase I Human Clinical Trial for Concussion Drug, Preparing for Phase II
Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
Las Vegas, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical product
Odyssey Health, Inc. Schedules Annual Meeting of Stockholders
Las Vegas, Nevada, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on d
Odyssey Health, Inc. Provides Recap on Concussion Drug Development
Las Vegas, Nevada, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical product
Odyssey Health, Inc. Makes Statement Regarding Its Concussion Drug Development Program
Las Vegas Nevada, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., (the "Company" "Odyssey") a company focused on developing a unique dru
Odyssey Health Rises 11% on Completing Phase 1 Trial of Concussion Treatment
Odyssey Health (OTCPK:ODYY) said it had completed the study of all cohorts for its Phase I Single Ascending Dosing and Multiple Ascending Dosing clinical trial of PRV-002, its drug to treat concussion
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II
Las Vegas, NV, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products,
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial
Las Vegas, NV, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, t
Odyssey Health, Inc. Announces Positive Results from Its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion
Las Vegas, NV, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-improving medical products, t
Company Overview
More
Odyssey Health, Inc. is a medical device technology and asset acquisition company. It engages in the development and acquisition of medical devices and health related technologies. The firm also owns technology and the marketing and distribution rights to CardioMap, which is intended to be an advanced technology for early non-invasive testing for heart disease. The company was founded in March 2014 and is headquartered in Las Vegas, NV.
CEO： --
Market： Pink Market
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet